Sites need to have a voice from the outset when working with vendors and sponsors to bring new or upgraded technology to bear on clinical trials.

Expect FDA to maintain use of “hybrid” inspection tools and tactics, agency official says.

ACRP talked to Chris Komelasky, CEO & Founder of Site Bridge Research, about what steps need to be taken to broaden clinical research into underserved and minority populations.